Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

TEVA - Finding Quality Trades With Institutional Backing

Friday 21 February 2014

Three days ago, Tuesday, we posted a Market Commentary with a
chart of TEVA, an Israeli pharmaceutical company. It was around 1
a.m., several hours prior to the stock market open. This was the
second paragraph:

For disclosure, we do not trade stocks, so this is just an
exercise. Were a position to be
taken, there is merit in a buy-
stop order at 44.68, with a protective sell stop at 42.25.

...We post this now, in case 44.68 does trigger, so the
recommendation would not appear to have been in hindsight.

More to come, soon.

This is the chart, as posted. The recommended buy stop was just
above the box area, at the end of the chart. TEVA had two noted
positives going for it: 1) A strong rally on very strong volume in mid-
January. Here is a clear example of institutional buying in a stock.
2) TEVA was building another TR, [Trading Range], base, which if the breakout were to be to the upside, the base supported a move much
higher, or at least somewhat higher.

TEVA D 18 Feb 13

An article was written, last November, Markets Talk Few Listen, in
which we presented the very same concept as a valid approach for
improving one's ability to make better trade selections. It explains
why early January was the time and price to buy TEVA. The chart
above shows a new trade that offers potential with a clearly defined

It turns out TEVA was one of the largest stock holdings in a Soros
Fund, at least as of last Quarter. That may or may not still hold true,
which is immaterial because the noted spike in volume was the
market's way of letting us know that institutions were buyers. It
does not matter which institution[s]. When they buy, they buy for
the longer term.

TEVA is measured against the pharmaceutical ETF, XPH, to
determine its strength within that sector. TEVA was ready to have an upside breakout at the same time as the ETF.

XPH D 21 Feb 14

TEVA is slightly under the similar chart structure of XPH. This would
prompt a closer look at other pharmaceutical stocks that may be
relatively stronger than TEVA, maybe even the ETF itself. It just
happens that TEVA was the hand we were dealt, at the time, and
mention is made to show how there is flexibility in how one wants
to determine the quality of potential stock selections.

The increased volume, last bar on the chart, would raise some
concern over the next day trade activity. The volume is similar to the January breakout volume, but the range of the bar is slightly smaller
than the January range. Just something over which to be aware.

Because the Fed-driven stock market is at an advanced stage, one
has to be quicker to respond to price activity, as opposed to say
were this kind of breakout occurring during the early stages of a
bull market, and one could exercise more patience.

Another way to be flexible is in the risk management of this trade.
The stop can be raised up to the breakeven level, eliminating risk
exposure entirely. On any further advance, profits can be taken on
half the position to ensure a profitable trade. The point is, do not
just buy and hold without taking an active role in managing each
stock selection.

TEVA D 21 Feb 14

Here is an updated TEVA hourly chart. Price gapped higher on
Tuesday morning, which would have triggered a 44.68 buy stop.
The recommended buy could have been filled in the 45.40 area,
with an initial stop-loss at 42.25, risking $3, initially.

TEVA 60m 21 Feb 14